Product image of Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate) supplied by GNH India

Oralair

Active Ingredient:
Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate
Origin:
EU

Oralair (Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate)

Allergen extract from pollen of Dactylis glomerata, Anthoxanthum odoratum, Lolium perenne, Poa pratensis, the active ingredient in Oralair, is an allergen immunotherapy presented as a sublingual tablet for sublingual use. It treats seasonal allergic rhinitis and grass‑pollen‑induced allergic rhinoconjunctivitis in patients with documented grass pollen sensitivity.

GNH India supplies Oralair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Stallergenes

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Oralair is used in allergen immunotherapy to modify the immune response to grass pollen exposure.

  • Seasonal allergic rhinitis (grass pollen): Reduces nasal congestion, sneezing, itching and improves overall symptom control during the grass pollen season.
  • Grass pollen‑induced allergic rhinoconjunctivitis: Alleviates ocular irritation and conjunctival symptoms while promoting long‑term tolerance to grass pollen allergens.
  • Preventive management of grass pollen allergy: Decreases the need for rescue medication and enhances quality of life for affected individuals.

How It Works

  • Oralair delivers standardized grass pollen allergen extracts sublingually, allowing repeated exposure to the immune system. This exposure shifts the T‑cell response from a Th2‑dominant profile toward Th1, promotes regulatory T‑cell activity, and increases allergen‑specific IgG4 antibodies, thereby inducing immune tolerance and reducing allergic inflammation upon natural pollen contact.

Side Effects

Oralair may cause adverse reactions, most of which are mild and localized.

Common Side Effects

  • Oral itching or tingling: mild discomfort in the mouth after tablet placement.
  • Throat irritation: transient soreness or scratchy sensation.
  • Mouth edema: slight swelling of the lips or tongue.
  • Mild gastrointestinal upset: occasional nausea or abdominal discomfort.
  • Headache: transient mild headache.

Serious or Rare Side Effects

  • Anaphylaxis: severe, potentially life‑threatening allergic reaction.
  • Systemic allergic reaction: widespread urticaria, bronchospasm, or hypotension.
  • Angioedema: rapid swelling of face, lips, or airway.
  • Severe asthma exacerbation: worsening of asthma symptoms requiring emergency care.

Precautions & Warnings

Before prescribing Oralair, clinicians should consider several safety aspects.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: discuss potential risks with a healthcare professional.
  • Concomitant immunotherapy: avoid simultaneous use of other allergen immunotherapies.
  • Uncontrolled asthma: contraindicated in patients with severe, uncontrolled asthma.
  • Age and suitability: prescribe only for patients for whom the prescriber determines appropriate use.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Avoid Interactions

Oralair may interact with certain medications, requiring careful management.

Major Interactions (Avoid)

  • Beta‑blockers: may increase severity of anaphylactic reactions.
  • Immunosuppressants: may diminish the therapeutic effect of the tablet.

Moderate Interactions (Monitor Closely)

  • Antihistamines: can mask early signs of an allergic reaction.
  • Systemic corticosteroids: may alter immune response to the allergen extract.
  • Other sublingual immunotherapy products: concurrent use may raise risk of overlapping exposure and adverse events.

Frequently Asked Questions

Oralair is a sublingual tablet containing grass pollen allergen extracts that is prescribed to treat seasonal allergic rhinitis and grass‑pollen‑induced allergic rhinoconjunctivitis. It works by gradually desensitizing the immune system to grass pollen, reducing nasal and ocular symptoms during the pollen season.

The allergen extract in Oralair is administered sublingually, exposing the immune system to controlled amounts of grass pollen proteins. This repeated exposure shifts immune signaling from a Th2‑dominant allergic response toward a Th1 and regulatory profile, increasing IgG4 production and promoting tolerance to natural grass pollen exposure.

The dosing regimen for Oralair is individualized and must be determined by a qualified healthcare professional. The prescriber selects the starting dose, titration schedule, and maintenance dose based on the patient’s age, severity of allergy, and clinical response.

Safety data for Oralair in pregnancy and lactation are limited. It should only be used if the potential benefit outweighs any possible risk, and the decision should be made in consultation with a healthcare provider who can evaluate the individual’s circumstances.

To order Oralair, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Oralair is a sublingual immunotherapy tablet, whereas alternative options include subcutaneous allergy shots and symptomatic antihistamines. Compared with injections, Oralair offers a non‑invasive, at‑home administration route and may provide longer‑term disease modification, while antihistamines only relieve symptoms without inducing tolerance.

Oralair tablets should be stored at ambient temperature below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and avoid exposing the tablets to excessive heat or humidity to maintain product stability.

Oralair is taken sublingually: the tablet is placed under the tongue and allowed to dissolve completely without swallowing, typically once daily as directed by the prescriber. Patients should avoid eating or drinking for a short period after administration to ensure optimal absorption.

The most serious risks include systemic allergic reactions such as anaphylaxis, severe asthma exacerbations, and angioedema. Patients should be monitored after the first dose and instructed to seek immediate medical attention if they experience symptoms like difficulty breathing, swelling of the face or throat, or a rapid drop in blood pressure.

Oralair is contraindicated in individuals with severe, uncontrolled asthma, those who have experienced a severe systemic reaction to a previous grass pollen immunotherapy, or patients receiving beta‑blocker therapy that cannot be discontinued. It should also be avoided in anyone for whom the prescriber determines the risks outweigh the benefits.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Allergen Extract From Pollen Of Dactylis Glomerata, Anthoxanthum Odoratum, Lolium Perenne, Poa Prate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT